INmune Bio
INMB
INMB
32 hedge funds and large institutions have $11.7M invested in INmune Bio in 2022 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 9 increasing their positions, 7 reducing their positions, and 6 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less ownership
Funds ownership: →
less funds holding
Funds holding: →
33% less capital invested
Capital invested by funds: $17.4M → $11.7M (-$5.7M)
33% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 6
Holders
32
Holding in Top 10
–
Calls
$350K
Puts
$157K
Top Buyers
| 1 | +$168K | |
| 2 | +$147K | |
| 3 | +$58.7K | |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$25K |
| 5 |
Group One Trading
Chicago,
Illinois
|
+$16.6K |
Top Sellers
| 1 | -$492K | |
| 2 | -$284K | |
| 3 | -$134K | |
| 4 |
Janney Montgomery Scott
Philadelphia,
Pennsylvania
|
-$98.2K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$75.9K |